Authors:Carvallo H, Hirsch RR, Alkis P, Contreras V. DOI:10.31546/2633-8653.1007 Abstract The severe acute respiratory syndrome-coronavirus-2 pandemic has had devastating health and socio-economic implications worldwide. Epidemiologic data indicate that SARS-CoV2 is spread by respiratory droplets and contact. The lack of acquired human immunity to the virus and the absence of a vaccine, has meant that current [...]

COVID-19 patients suffer from the lack of curative therapy. Hence, there is an urgent need to try repurposed old drugs on COVID-19. Methods Randomized controlled study on 70 COVID-19 patients (48 mild-moderate, 11 severe, and 11 critical patients) treated with 200ug/kg PO of Ivermectin per day for 2-3 days along with 100mg PO doxycycline twice per day for 5-10 days plus standard therapy; the second arm is 70 COVID-19 patients (48 mild-moderate and 22 severe and zero critical patients) on standard therapy. The time to recovery, the progression of the disease, and the mortality rate were the outcome-assessing parameters.

Authors: Hashim HA, Maulood MF, rasheed AM, Fatak DF, Kabah KK. doi: https://doi.org/10.1101/2020.10.26.20219345 Abstract Objectives COVID-19 patients suffer from the lack of curative therapy. Hence, there is an urgent need to try repurposed old drugs on COVID-19. Methods Randomized controlled study on 70 COVID-19 patients (48 mild-moderate, 11 severe, and 11 [...]

Authors: Chamie J Abstract In these eight Peruvian State analyses, Ivermectin distributions preceded sound reductions in excess deaths and case fatality rate (CFR). The variation in the number of detected cases nor the vulnerable population decrease can explain this reduction. Other possible explanations, such as cross-immunity with dengue, or mere causality, have been discarded due [...]

Authors: Lehrer S, Rheinstein PH PMID: 32871846 PMCID: PMC7652439 DOI: 10.21873/invivo.12134 Abstract Background/aim: Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). One drug that has attracted interest is the antiparasitic compound ivermectin, a macrocyclic lactone derived from the bacterium Streptomyces avermitilis. We carried out a docking [...]

Authors: DiNicolantonio JJ, Barroso-Arranda J, McCarty M PMID: 32895293 PMCID: PMC7476419 DOI: 10.1136/openhrt-2020-001350 Abstract Ivermectin, on the WHO’s List of Essential Medications, has been in clinical use since 1981 as an orally and topically active agent for treating a range of parasitic infections in humans, including river blindness and lymphatic filariasis. It is also widely [...]

Authors:.= Khan MS, Khan MS, Debnath Cr, Nath PN, Mahtab MA. PMID: 33293006 PMCID: PMC7837160 DOI: 10.1016/j.arbres.2020.08.007 Abstract The pandemic coronavirus disease 19 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been spread rapidly worldwide with considerable morbidity and mortality. COVID-19 patients have various clinical presentations: asymptomatic, exhibit mild flu-like symptoms, be [...]

Authors: Jans DA, Wagstaff KM PMID: 32942671 PMCID: PMC7564151 DOI: 10.3390/cells9092100 Abstract The small molecule macrocyclic lactone ivermectin, approved by the US Food and Drug Administration for parasitic infections, has received renewed attention in the last eight years due to its apparent exciting potential as an antiviral. It was identified in a high-throughput chemical screen [...]

Authors: Swargiary A DOI: https://doi.org/10.21203/rs.3.rs-73308/v1 Abstract Purpose: COVID-19, caused by SARS-CoV2 virus is a contagious disease affecting millions of lives throughout the globe. Currently, there are no clinically approved drugs for SARS-CoV2 although some drugs are undergoing clinical trials. The present study investigates the binding property of ivermectin on four important drug targets, spike protein, [...]

Authors: DiNicolantonio JJ, Barroso-Arranda J, McCarty M PMID: 32895293 PMCID: PMC7476419 DOI: 10.1136/openhrt-2020-001350 Abstract Ivermectin, on the WHO’s List of Essential Medications, has been in clinical use since 1981 as an orally and topically active agent for treating a range of parasitic infections in humans, including river blindness and lymphatic filariasis. It is also widely [...]